Making breast cancer risk clear for women of all ancestries
MyRisk® with RiskScore® estimates an individual patient’s 5-year and lifetime breast cancer risk based on medical history, family history, and genetic markers. Myriad was the first and only lab to make these answers available and accurate for patients of any ancestry.
Meet MyRisk with RiskScore
Request more information or explore ordering options to bring MyRisk hereditary cancer testing to your practice.
What is MyRisk with RiskScore?
For patients with family history of certain cancers, hereditary cancer testing is the primary way to determine if they are at an increased risk of developing specific types of cancer.
MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk. When combined with family history and other clinical factors, MyRisk with RiskScore provides each patient with a cancer risk assessment individualized to them.
Nearly 1 in 4 patients1 meet criteria for hereditary cancer testing
Who is eligible?
Nearly 1 in 4 patients meet the criteria for hereditary cancer testing. Patients may be eligible if someone in their family has been diagnosed with:
- Breast cancer at age 50 or younger
- Ovarian cancer at any age
- Pancreatic cancer at any age
- Metastatic prostate cancer at any age
- Male breast cancer at any age
Give your patients a complete answer
When it comes to assessing breast cancer risk, MyRisk goes a step further by giving patients who receive a negative test result a RiskScore.
RiskScore is a component of the MyRisk test that provides a personalized estimate of a person’s likelihood to develop breast cancer over the next 5 years and their lifetime, guiding patients and providers to make more confident and informed medical decisions for managing breast cancer risk.
Take the next step with MyRisk
Get started by downloading the provider guide to learn more.
Hear from patients whose lives have been transformed
Why choose MyRisk?
Lowest
BRCA1/2 VUS rates
With MyRisk, leverage the industry’s lowest BRCA1/2 VUS rates for clarity in treatment decisions.2
Double
Amount of mutations detected
Panel testing can detect nearly double the amount of mutations compared to single gene testing.3
53%
MyRisk helps patients qualify
53% of patients tested with MyRisk qualify for a change in their medical management vs. approximately 10% expected if tested with other labs.4
Testing process made easy
Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice.
1. Patient identification
OPTIONS
- Digital screening with MyGeneHistory™
- Radiology Information Systems
- Mammography Information Systems
2. Pre-test education
(with board-certified genetic counselor)
INCLUDES
- Individualized education (on-demand)
- Follow-up documentation (pre-populated test request form, three-generation pedigree, chart notes)
3. Ordering
OPTIONS
- Online portal
- Virtual/paper orders
- EMR integrations
- Phlebotomy support
- Technical/ordering support
4. Affordability
INCLUDES
- Personalized cost estimates
- 9/10 patients pay $0 ($54 average)
- Financial assistance and payment plans available
5. Results
INCLUDES
- Personalized Tyrer-Cuzick/RiskScore with a 5-year and lifetime risk (when applicable)
- Online portal or results by mail
- EMR integration
- Medical management tool included
6. Post-test discussions
(with board-certified genetic counselor)
INCLUDES
- Individualized discussion of results (on‑demand or scheduled)
- Detailed summary of notes
Testing process made easy
Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice.
MyRisk hereditary cancer 48 gene panel
| Genes | Breast | Ovarian | Colorectal | Uterine | Skin | Pancreatic | Gastric | Prostate | Renal | Lung | Endocrine | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRCA1 |
|
|
|
|
||||||||
| BRCA2 |
|
|
|
|
|
|||||||
| MLH1 |
|
|
|
|
|
|
|
|
||||
| MSH2 |
|
|
|
|
|
|
|
|
||||
| MSH6 |
|
|
|
|
|
|
|
|
||||
| PMS2 |
|
|
|
|
|
|
|
|
||||
| EPCAM |
|
|
|
|
|
|
|
|
||||
| CTNNA1 |
|
|||||||||||
| APC |
|
|
|
|
||||||||
| MUTYH Monoallelic | ||||||||||||
| MUTYH Biallelic |
|
|
||||||||||
| CDKN2A (p16INK4a) |
|
|
||||||||||
| CDKN2A (p14ARF) |
|
|
||||||||||
| CDK4 |
|
|
||||||||||
| TP53 |
|
|
|
|
|
|
|
|
|
|||
| PTEN |
|
|
|
|
|
|
|
|||||
| STK11 |
|
|
|
|
|
|
|
|
||||
| CDH1 |
|
|
||||||||||
| PALB2 |
|
|
|
|||||||||
| ATM |
|
|
|
|||||||||
| CHEK2 |
|
|
||||||||||
| CHEK2 Biallelic |
|
|
||||||||||
| RAD51C |
|
|
||||||||||
| RAD51D |
|
|
||||||||||
| BARD1 |
|
|||||||||||
| BRIP1 |
|
|||||||||||
| BMPR1A |
|
|
|
|||||||||
| SMAD4 |
|
|
|
|||||||||
| VHL |
|
|
|
|||||||||
| RET |
|
|
||||||||||
| MEN1 |
|
|
||||||||||
| BAP1 |
|
|
|
|||||||||
| TSC1 |
|
|
||||||||||
| TSC2 |
|
|
||||||||||
| FH |
|
|
|
|||||||||
| FLCN |
|
|
|
|||||||||
| TERT |
|
|||||||||||
| MITF |
|
|||||||||||
| MET |
|
|||||||||||
| SDHA |
|
|
|
|||||||||
| SDHB |
|
|
|
|||||||||
| SDHC |
|
|
|
|||||||||
| SDHD |
|
|
|
|||||||||
| POLD1 |
|
|||||||||||
| POLE |
|
|||||||||||
| GREM1 |
|
|||||||||||
| AXIN2 |
|
|||||||||||
| NTHL1 Monoallelic | ||||||||||||
| NTHL1 Biallelic |
|
|
|
|
||||||||
| MSH3 Monoallelic | ||||||||||||
| MSH3 Biallelic |
|
|||||||||||
| HOXB13 |
|
|||||||||||
| EGFR |
|
MyRisk testing provides you with clear results you can trust
Most hereditary cancer tests only produce positive or negative results. MyRisk takes this a step further, including the MyRisk Management Tool in every report. This easy-to-use guide breaks down everything you need to know about using these results to inform your patient’s personal care plan today and in the future.
Precision insights to get ahead of cancer
RiskScore estimates an individual patient’s 5-year and lifetime breast cancer risk based on medical history, family history, and genetic markers. Myriad was the first and only lab to make this precision answer available and accurate for patients of any ancestry.
Our research studies
Take the first step towards more informed, personalized cancer care for your patients.
References:
- DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstetrics & Gynecology 2018 – published online before print October 10, 2018.
- Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019.
- Yorczyk A, et al. Use of panel tests in place of single gene tesets in the cancer genetics clinic. Clin Genet. 2015 Sep;88(3):278-282.
- Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.
